Surred by politics and public backlash, drug pricing has been the hot button issue for the pharma industry for more than two years now. And while how to price your drugs has always been a complex issue for pharma and biotechs alike, this new environment has made it particularly important to start engaging with payers as early in the drug development process as possible.
Every biotech knows that payers are the gatekeepers to the market and, ultimately, to patients.
